EP4076525A4 - ANTIBODIES AGAINST ALPHA 11 BETA 1 INTEGRIN - Google Patents

ANTIBODIES AGAINST ALPHA 11 BETA 1 INTEGRIN Download PDF

Info

Publication number
EP4076525A4
EP4076525A4 EP20903433.9A EP20903433A EP4076525A4 EP 4076525 A4 EP4076525 A4 EP 4076525A4 EP 20903433 A EP20903433 A EP 20903433A EP 4076525 A4 EP4076525 A4 EP 4076525A4
Authority
EP
European Patent Office
Prior art keywords
integrin
beta
antibodies against
against alpha
alpha
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP20903433.9A
Other languages
German (de)
French (fr)
Other versions
EP4076525A1 (en
Inventor
Elma KURTAGIC
James W. MEADOR III
JR. Christopher BENEDUCE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Momenta Pharmaceuticals Inc
Original Assignee
Momenta Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Momenta Pharmaceuticals Inc filed Critical Momenta Pharmaceuticals Inc
Publication of EP4076525A1 publication Critical patent/EP4076525A1/en
Publication of EP4076525A4 publication Critical patent/EP4076525A4/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP20903433.9A 2019-12-20 2020-12-18 ANTIBODIES AGAINST ALPHA 11 BETA 1 INTEGRIN Pending EP4076525A4 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962951723P 2019-12-20 2019-12-20
US202062983155P 2020-02-28 2020-02-28
US202063054717P 2020-07-21 2020-07-21
PCT/US2020/066107 WO2021127500A1 (en) 2019-12-20 2020-12-18 Antibodies against integrin alpha 11 beta 1

Publications (2)

Publication Number Publication Date
EP4076525A1 EP4076525A1 (en) 2022-10-26
EP4076525A4 true EP4076525A4 (en) 2024-05-01

Family

ID=76478574

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20903433.9A Pending EP4076525A4 (en) 2019-12-20 2020-12-18 ANTIBODIES AGAINST ALPHA 11 BETA 1 INTEGRIN

Country Status (18)

Country Link
US (2) US12460006B2 (en)
EP (1) EP4076525A4 (en)
JP (2) JP2023508286A (en)
KR (1) KR20220123013A (en)
CN (1) CN115135342A (en)
AU (1) AU2020407124A1 (en)
BR (1) BR112022012093A2 (en)
CA (1) CA3165386A1 (en)
CL (1) CL2022001673A1 (en)
CO (1) CO2022010204A2 (en)
CR (1) CR20220288A (en)
DO (1) DOP2022000129A (en)
EC (1) ECSP22056627A (en)
IL (1) IL294047A (en)
MX (1) MX2022007521A (en)
PE (1) PE20221723A1 (en)
PH (1) PH12022551471A1 (en)
WO (1) WO2021127500A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240317865A1 (en) * 2020-12-18 2024-09-26 Momenta Pharmaceuticals, Inc. Antibodies against integrin alpha 11 beta 1
JPWO2023238845A1 (en) * 2022-06-07 2023-12-14
CA3258452A1 (en) * 2022-06-22 2023-12-28 Momenta Pharmaceuticals, Inc. Antibodies against integrin alpha 11 beta 1 and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1181317B1 (en) * 1999-06-03 2011-07-20 Cartela R & D AB An integrin heterodimer and an alpha subunit thereof
EP3524625A1 (en) * 2018-02-08 2019-08-14 Bergen Teknologioverforing AS Antibody against alpha-11 integrin and its use
WO2019168176A1 (en) * 2018-03-01 2019-09-06 国立大学法人広島大学 ANTI-INTEGRIN α11 MONOCLONAL ANTIBODY AND USE THEREOF

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
IL79289A (en) 1985-07-05 1992-01-15 Whitehead Biomedical Inst Introduction and expression of foreign genetic material into keratinocytes using a recombinant retrovirus
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
EP0281604B1 (en) 1986-09-02 1993-03-31 Enzon Labs Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
ATE117375T1 (en) 1987-09-11 1995-02-15 Whitehead Biomedical Inst TRANSDUCTION ALTERED FIBROBLASS AND THEIR APPLICATION.
JP2914692B2 (en) 1987-12-11 1999-07-05 ホワイトヘツド・インスチチユート・フオー・バイオメデイカル・リサーチ Endothelial cell genetic modification
WO1989007136A2 (en) 1988-02-05 1989-08-10 Whitehead Institute For Biomedical Research Modified hepatocytes and uses therefor
DE3920358A1 (en) 1989-06-22 1991-01-17 Behringwerke Ag BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
ES2096750T3 (en) 1990-10-31 1997-03-16 Somatix Therapy Corp USEFUL RETROVIRIC VECTORS FOR GENIC THERAPY.
ATE207080T1 (en) 1991-11-25 2001-11-15 Enzon Inc MULTIVALENT ANTIGEN-BINDING PROTEINS
SE9201984D0 (en) 1992-06-29 1992-06-29 Pharmacia Biosensor Ab IMPROVEMENT IN OPTICAL ASSAYS
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
DK1621554T4 (en) 1992-08-21 2012-12-17 Univ Bruxelles Immunoglobulins devoid of light chains
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
ES2162863T3 (en) 1993-04-29 2002-01-16 Unilever Nv PRODUCTION OF ANTIBODIES OR FRAGMENTS (FUNCTIONALIZED) OF THE SAME DERIVED FROM HEAVY CHAIN IMMUNOGLOBULINS OF CAMELIDAE.
US5308341A (en) 1993-09-28 1994-05-03 Becton, Dickinson And Company Method of testing the dose accuracy of a medication delivery device
US6146361A (en) 1996-09-26 2000-11-14 Becton Dickinson And Company Medication delivery pen having a 31 gauge needle
US6302855B1 (en) 1998-05-20 2001-10-16 Novo Nordisk A/S Medical apparatus for use by a patient for medical self treatment of diabetes
GB9818110D0 (en) 1998-08-19 1998-10-14 Weston Medical Ltd Needleless injectors and other devices
US6096002A (en) 1998-11-18 2000-08-01 Bioject, Inc. NGAS powered self-resetting needle-less hypodermic jet injection apparatus and method
US6192891B1 (en) 1999-04-26 2001-02-27 Becton Dickinson And Company Integrated system including medication delivery pen, blood monitoring device, and lancer
US6277099B1 (en) 1999-08-06 2001-08-21 Becton, Dickinson And Company Medication delivery pen
US7083784B2 (en) 2000-12-12 2006-08-01 Medimmune, Inc. Molecules with extended half-lives, compositions and uses thereof
WO2003022330A2 (en) 2001-09-12 2003-03-20 Becton, Dickinson And Company Microneedle-based pen device for drug delivery and method for using same
FR2849436B1 (en) 2002-12-27 2007-01-05 Patrick Frayssinet PARTICLES AND CERAMICS OF CALCIUM PHOSPHATES FOR TRANSFECTION IN VIVO AND IN VITRO
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
WO2008068481A1 (en) * 2006-12-05 2008-06-12 Cartela R & D Ab New compounds, methods and uses
CA2709411A1 (en) * 2006-12-18 2008-06-26 Cartela R&D Ab Binding agents to the integrin alpha-11 subunit, and uses thereof
EP3037819A4 (en) 2013-08-23 2017-03-29 Fujita Health University Method of determining resistance to influenza virus
WO2015161247A1 (en) 2014-04-17 2015-10-22 Igenica Biotherapeutics, Inc. Humanized anti-c16orf54 antibodies and methods of use thereof
US9840557B2 (en) 2014-09-23 2017-12-12 Regeneron Pharmaceuticals, Inc. Anti-IL-25 antibodies and uses thereof
KR20180100302A (en) * 2015-10-23 2018-09-10 우니베르지태트 트벤테 Integrin binding peptides and uses thereof
EP3458157A4 (en) 2016-05-19 2020-05-27 Momenta Pharmaceuticals, Inc. Methods for treating disorders associated with fibrosis and systemic sclerosis
EP3517549A1 (en) * 2018-01-24 2019-07-31 Bergen Teknologioverforing AS Antibody against alpha-11 integrin and its use
US20240317865A1 (en) 2020-12-18 2024-09-26 Momenta Pharmaceuticals, Inc. Antibodies against integrin alpha 11 beta 1

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1181317B1 (en) * 1999-06-03 2011-07-20 Cartela R & D AB An integrin heterodimer and an alpha subunit thereof
EP3524625A1 (en) * 2018-02-08 2019-08-14 Bergen Teknologioverforing AS Antibody against alpha-11 integrin and its use
WO2019168176A1 (en) * 2018-03-01 2019-09-06 国立大学法人広島大学 ANTI-INTEGRIN α11 MONOCLONAL ANTIBODY AND USE THEREOF

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
See also references of WO2021127500A1 *
ZELTZ CÉDRIC ET AL: "[alpha]11[beta]1 Integrin is Induced in a Subset of Cancer-Associated Fibroblasts in Desmoplastic Tumor Stroma and Mediates In Vitro Cell Migration", CANCERS, vol. 11, no. 6, 1 June 2019 (2019-06-01), CH, pages 765, XP055851973, ISSN: 2072-6694, DOI: 10.3390/cancers11060765 *

Also Published As

Publication number Publication date
KR20220123013A (en) 2022-09-05
US20260042845A1 (en) 2026-02-12
CL2022001673A1 (en) 2023-02-03
DOP2022000129A (en) 2022-10-31
ECSP22056627A (en) 2022-11-30
PE20221723A1 (en) 2022-11-04
CO2022010204A2 (en) 2022-10-21
BR112022012093A2 (en) 2022-08-30
CN115135342A (en) 2022-09-30
US12460006B2 (en) 2025-11-04
PH12022551471A1 (en) 2023-04-24
WO2021127500A1 (en) 2021-06-24
US20230050972A1 (en) 2023-02-16
AU2020407124A1 (en) 2022-07-21
CA3165386A1 (en) 2021-06-24
WO2021127500A9 (en) 2021-07-29
MX2022007521A (en) 2022-07-19
JP2025160182A (en) 2025-10-22
CR20220288A (en) 2022-10-07
IL294047A (en) 2022-08-01
JP2023508286A (en) 2023-03-02
EP4076525A1 (en) 2022-10-26

Similar Documents

Publication Publication Date Title
EP3740508A4 (en) ANTIBODIES AND ASSOCIATED VARIANTS DIRECTED AGAINST TIGIT
EP3950716A4 (en) ANTI-CLAUDINE 18.2 ANTIBODIES AND USE
EP3618871A4 (en) ANTI-LAG3 ANTIBODIES ETCO-FORMULATIONS ANTI-LAG3 ANTIBODIES AND ANTI-PD-1 ANTIBODIES
EP3784699A4 (en) OPTIMIZED ANTI-TL1A ANTIBODIES
EP3735685A4 (en) BILLBOARD
EP3807318A4 (en) MULTI-SPECIFIC ANTIBODY CONSTRUCTIONS
EP3705496A4 (en) ANTIBODY VARIANT AND ISOFORM WITH REDUCED BIOLOGICAL ACTIVITY
EP3926701A4 (en) BILLBOARD
EP3750149C0 (en) BILLBOARD
EP3999545A4 (en) ANTI-CD73 ANTIBODIES AND ITS APPLICATION
EP3971208A4 (en) ANTIBODY AGAINST CLAUDINE 18A2 AND ITS USE
MA55600A (en) ANTI-IGE ANTIBODIES
EP3798719A4 (en) BILLBOARD
EP4041284A4 (en) IGF2 VARIANT CONSTRUCTS
IL292716A (en) Pro-perfume preparations
EP3518973A4 (en) NEUTRALIZING ANTIBODIES AGAINST THE ALPHA V BETA 8 INTEGRIN COMPLEX FOR IMMUNOTHERAPY
MA51903A (en) B7-H4 ANTIBODY FORMULATIONS
MA54052A (en) ANTIBODY FORMULATION
EP3823978A4 (en) ANTI-CRNF ANTIBODY COMPOSITIONS
EP3613770A4 (en) MONOCLONAL ANTIBODY AT PD-L1
MA56466A (en) ANTI-EPHA4 ANTIBODIES
EP4076525A4 (en) ANTIBODIES AGAINST ALPHA 11 BETA 1 INTEGRIN
EP3982415A4 (en) BILLBOARD
EP3676294A4 (en) ANTI-CD ANTIBODIES AND THEIR MANUFACTURING AND USE PROCEDURES
EP3947466A4 (en) ANTI-HLA-DQ2.5 ANTIBODIES

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20220713

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40082069

Country of ref document: HK

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61K0039395000

Ipc: C07K0016280000

A4 Supplementary search report drawn up and despatched

Effective date: 20240403

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 39/00 20060101ALI20240326BHEP

Ipc: C12P 21/08 20060101ALI20240326BHEP

Ipc: A61K 39/395 20060101ALI20240326BHEP

Ipc: C07K 16/28 20060101AFI20240326BHEP